Access Vascular

Access Vascular, Inc. develops vascular access devices intended to address common complications associated with indwelling catheters. Its product family includes HydroPICC peripherally inserted central catheters and HydroMID midline catheters, which use the company’s patented MIMIX technology and a novel hydrophilic biomaterial. The material is designed to reduce thrombosis, a leading cause of catheter complications, without relying on coatings, fillers, or surface modifications.

The company reports that its devices have demonstrated fewer complications than standard polyurethane catheters in clinical, in vivo, and in vitro data. Reported findings include six times fewer complications with HydroMID and 99.99% less bacterial adhesion than polyurethane in a blood-loop model. Access Vascular also highlights potential benefits such as fewer device replacements, needle sticks, and treatment delays. An economic study cited by the company estimates potential savings of up to $1.8 million for a large acute care hospital through reduced complications. The company provides product information, technology and data resources, education, and customer support.